Misbranding is a legal violation that occurs when a drug’s labeling is false, misleading, or missing required information. Under federal law, specifically Section 502 of the Food, Drug, and Cosmetic (FD&C) Act, a drug is considered misbranded if anything on its label or packaging could deceive or inadequately inform the person using it. This applies to manufacturers, distributors, and pharmacies alike, and it carries real penalties including fines and imprisonment.
What Counts as Misbranding
The legal definition is broad on purpose. A drug is misbranded if its labeling is “false or misleading in any particular.” That single phrase covers everything from outright lies about what a product does to subtler problems like leaving out important safety warnings. But misbranding goes well beyond just false claims. A drug in package form is also misbranded if it fails to list the name and place of business of the manufacturer, packer, or distributor, or if it doesn’t include an accurate statement of the quantity of contents by weight, measure, or count.
There’s also a readability requirement that many people don’t realize exists. Any information required on a label must be placed prominently enough, and written clearly enough, that an ordinary person can read and understand it under normal conditions of purchase and use. Burying a critical warning in tiny print at the bottom of a label can itself be a misbranding violation, even if the warning is technically present.
A drug is also misbranded if its labeling lacks adequate directions for use, adequate warnings about dangerous conditions, or proper cautions about unsafe dosage, methods, or duration of use.
How Misbranding Differs From Adulteration
These two terms come up together often, but they address different problems. Adulteration is about what’s actually inside the product: contamination, incorrect ingredients, manufacturing in unsanitary conditions, or a drug that doesn’t meet its stated strength or purity. Misbranding is about what’s on the outside: the label, the packaging, the promotional materials, the claims being made. A drug can be perfectly manufactured but still misbranded because its label is wrong. And a drug can have an accurate label but be adulterated because the contents are contaminated. In some cases, a product violates both at the same time.
Prescription Drugs vs. Over-the-Counter Drugs
The labeling rules differ significantly between prescription and OTC medications, which means the ways they get misbranded differ too.
Prescription drug labeling is reviewed and approved during the new drug application process. It must include prescribing information, use in specific populations, risk summaries, and data from clinical studies. The most common labeling violations for prescription drugs tend to involve misprints on primary packaging or container labels, things like incorrect drug names, wrong strengths, or missing lot numbers.
OTC drugs follow a different path. Their labeling must conform to a standardized “Drug Facts” format covering uses, warnings, directions, and active ingredients, as outlined in federal regulations. Because consumers use these products without a prescriber’s guidance, accurate labeling is the only safety net. An analysis of FDA warning letters from 2015 to 2019 found that misbranding was the most common violation category for OTC products, accounting for 29% of all cited violations. The most frequent issue: OTC labels making therapeutic claims without any scientific support. When an OTC product includes ingredients that deviate from its approved monograph or makes unsupported health claims, it can be reclassified as both an unapproved new drug and a misbranded product.
Certain prescription drugs also require Patient Package Inserts. Oral contraceptives and estrogen-containing products, for instance, must include FDA-approved inserts with every dispensed package. Failing to provide these inserts is itself a form of misbranding, because the drug’s labeling is considered incomplete without them.
How Misbranding Applies to Compounding Pharmacies
Compounding pharmacies, which prepare customized medications for individual patients, operate under special rules. Sections 503A and 503B of the FD&C Act give compounding pharmacies exemptions from certain labeling requirements, including the standard requirement for “adequate directions for use” that applies to manufactured drugs. These exemptions exist because compounded drugs are typically prepared for a specific patient with a specific prescription.
However, those exemptions come with conditions. If a compounding pharmacy fails to meet the requirements laid out in Sections 503A or 503B, such as compounding without valid prescriptions, producing drugs in bulk for general distribution, or using ingredients that aren’t permitted, the exemptions disappear. At that point, every standard labeling and approval requirement kicks back in, and the products become subject to misbranding (and potentially unapproved new drug) charges. The FDA has been enforcing this boundary since at least 1992, when it issued a compliance policy guide specifically addressing the manufacture, distribution, and promotion of misbranded drugs by state-licensed pharmacies.
A notable example of how these issues intersect with patient safety: in 2010, the FDA investigated a cluster of serious bacterial eye infections in patients who received injections of a drug repackaged by a pharmacy in Tennessee. Repackaging introduces its own labeling and handling requirements, and failures at that stage can create both misbranding and safety problems simultaneously.
Drug Promotion and Advertising Violations
Misbranding extends beyond the physical label on a bottle. How a drug is promoted, whether through advertising, sales materials, or online marketing, falls under the same legal framework. The FDA’s Bad Ad Program identifies several common promotion violations that constitute misbranding:
- Omitting or downplaying risks while highlighting benefits
- Overstating what a drug can do beyond what clinical data supports
- Failing to present fair balance between risk and benefit information
- Misrepresenting study data or making misleading comparisons to other drugs
- Promoting investigational drugs that haven’t been approved
This is where misbranding charges frequently hit companies hard. Promoting a drug for uses it hasn’t been approved for (off-label promotion) is one of the most common triggers. The drug itself might be legitimately manufactured, but if the company markets it for conditions it hasn’t been proven to treat, the product is considered misbranded because its labeling effectively becomes misleading.
What the FDA Is Flagging Right Now
A look at FDA warning letters from 2024 reveals a clear pattern. The most frequently cited category is “Unapproved New Drugs/Misbranded,” and the targets are telling. Multiple warning letters went to companies selling peptides, research chemicals, and topical numbing creams (particularly products marketed to tattoo customers) that were making drug claims without FDA approval. These products were being sold as if they were approved pharmaceuticals, with therapeutic claims on their labels or websites, but had never gone through the approval process.
This “unapproved new drug plus misbranding” combination is the FDA’s most common enforcement pairing. When a product makes health claims that effectively turn it into a drug in the eyes of the law, it simultaneously becomes an unapproved drug and a misbranded one, because it lacks the required labeling elements that approved drugs must carry.
Penalties for Misbranding
Federal penalties for misbranding are structured in tiers. A first offense can result in up to one year of imprisonment, a fine of up to $1,000, or both. If someone commits a misbranding violation after a prior conviction, or if the violation involved intent to defraud or mislead, the penalties jump to up to three years of imprisonment and fines up to $10,000.
Civil penalties add another layer. For device-related misbranding violations, fines can reach $15,000 per violation and up to $1,000,000 for all violations in a single proceeding. For companies that run false or misleading direct-to-consumer drug advertising, civil penalties can reach $250,000 for a first violation within a three-year period and $500,000 for each subsequent violation.
Beyond federal penalties, state pharmacy boards can take their own disciplinary action, including suspending or revoking a pharmacy’s license. For pharmacists and pharmacy technicians, a misbranding violation can mean the end of a career, since state boards typically treat federal violations as grounds for license revocation.